|
【结 构 式】 
|
【药物名称】 【化学名称】2,3,4-Tri-O-acetyl-1-O-(3-butyl-3-ethyl-5-phenyl-2,3,4,5-tetrahydro-1,4-benzothiazepin-8-yl)-beta-D-glucopyranuronic acid methyl ester S,S-dioxide 【CA登记号】 【 分 子 式 】C34H43NO12S 【 分 子 量 】689.78531 |
【开发单位】Aventis Pharma (Originator) 【药理作用】Atherosclerosis Therapy, CARDIOVASCULAR DRUGS, Lipoprotein Disorders, Treatment of , METABOLIC DRUGS, Treatment of Disorders of the Coronary Arteries and Atherosclerosis, Ileal Bile Acid Transporter Inhibitors |
合成路线1
By condensation of D-glucopyranuronic acid methyl ester (I) with 3-butyl-3-ethyl-5-phenyl-2,3,4,5-tetrahydro-1,4-benzothiazepin-8-ol S,S-dioxide (III) by means of Tms-OTf.
| 【1】 Walker, E.H.; Palomino, E.; Blumenthal, S.L.; Carbohydrate prodrugs: potential use for in situ activation and drug delivery. Drugs Fut 1991, 16, 11, 1029. |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (I) | 42779 | methyl (2S,3R,4S,5R,6S)-3,4,5-tris(acetoxy)-6-hydroxytetrahydro-2H-pyran-2-carboxylate | C13H18O10 | 详情 | 详情 | |
| (II) | 42780 | (trimethylsilyl)[(2S,3R,4S,5R,6S)-3,4,5-tris(acetoxy)-6-(methoxycarbonyl)tetrahydro-2H-pyran-2-yl]oxonium trifluoromethanesulfonate | C17H27F3O13SSi | 详情 | 详情 | |
| (III) | 42781 | 3-butyl-3-ethyl-8-hydroxy-5-phenyl-2,3,4,5-tetrahydro-1H-1lambda(6),4-benzothiazepine-1,1-dione | C21H27NO3S | 详情 | 详情 |
Extended Information